Edwards Lifesciences enters the back half of August with a notable split in signals: short sellers are exiting at pace while the Street has spent the past month lifting targets and adding fresh buy ratings.
The short-interest retreat is the most striking move in the data. Bears have covered aggressively — short interest dropped 28.5% over the week to 1.55% of free float, and is down 14% over the past month. That decline brings the absolute short position to its lowest level in the 30-day window, with roughly 9 million shares short compared to over 12.7 million as recently as early August. The borrow market reflects the same ease: cost to borrow is running near 0.47%, down 13% on the week, and availability is extremely loose at over 6,800% — meaning for every share currently lent out, there are roughly 68 shares still available to borrow. There is no squeeze pressure here, and nothing in the lending market that could mechanically force further covering.
Options positioning is mildly defensive but unremarkable. The put/call ratio is 1.08, just a fraction above its 20-day mean of 1.06, and the z-score is near zero. That's well within normal ranges and a long way from the 52-week high of 2.18. The ORTEX short score has also been drifting lower — from 32.6 on August 10 down to 30.0 this week — confirming that the overall short-side signal has weakened, not strengthened. The short score ranks in the 74th percentile of the universe, but the direction of travel has been firmly toward less bearish positioning.
The Street view tilted decisively bullish in late July, following the Q2 print. UBS assumed coverage with a Buy and a $110 target. Leerink Partners upgraded to Outperform, lifting its target from $87 to $101. JP Morgan raised its target to $105 while holding Overweight. Multiple other firms — Piper Sandler, Mizuho, RBC, Citigroup, Evercore — all moved their targets higher in the same window, with several landing at $110. The consensus mean target now sits at $101, implying around 11% upside to the current price near $91. Analyst recommendation divergence ranks in the 93rd percentile of the universe — meaning the skew toward buy ratings is wider than almost all other names covered. The bull case centres on TAVR revenue growth of 10.6% year-on-year and TMTT sales expanding nearly 50%, with management guiding toward $6.4–6.8 billion in total revenue. Bears flag the margin miss — adjusted operating margin came in at 23.7% against a 25.9% consensus — and point to growing TAVR competition and softer surgical structural heart sales as reasons for caution on the growth trajectory.
Valuation multiples have moved modestly higher over the past month. The P/E has expanded around 1.5 turns to 28.3x, and price-to-book has added roughly 0.3x to 4.6x. EV/EBITDA has drifted in the opposite direction, down about 0.4x to 21.5x — suggesting the earnings-based re-rating has been modest rather than a full-on multiple expansion. Factor scores are mixed: EPS surprise ranks only in the 31st percentile, and EPS momentum over 90 days sits in the 44th — not a picture of a company that consistently beats. The most recent earnings print illustrates this: the stock fell 2.1% the day after the Q2 report on July 23, though it recovered to post a 3% gain over the following five trading days, suggesting the initial reaction was an overcooked pullback.
Insider activity has been one-way: every transaction in the past 90 days has been a sale, including a $245,000 sale by CEO Bernard Zovighian on July 27. The aggregate net value over 90 days shows over $5 million in stock sold. The trades are relatively small as a percentage of the company's shares outstanding, and VP-level routine selling is common around vesting schedules, but the absence of any buy-side insider activity at these price levels is worth noting alongside the broadly bullish analyst tone.
Correlated peers had a divergent week. ISRG fell 2.5% in line with EW's own 2.9% decline. GMED and ATEC both gained around 1.5–1.7%, widening the performance gap versus EW. BFLY was the weakest in the group, dropping 3.9%. The next scheduled catalyst is the Q3 earnings release, pencilled in for October 23 — and the pattern of post-earnings recoveries after initial-day weakness is worth tracking as that date approaches.
See the live data behind this article on ORTEX.
Open EW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
